A decade ago, there were dire concerns that the biopharmaceutical industry was headed for a severe crisis. There was, it was thought, inadequate mammalian manufacturing capacity to support the development pipeline. In particular, fears grew about sho…
Eric A. Langer, BioPlan Associates 03.07.14